TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Holdings Cut by Algert Global LLC

Algert Global LLC cut its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 52.9% during the 4th quarter, Holdings Channel reports. The firm owned 49,061 shares of the biopharmaceutical company’s stock after selling 55,191 shares during the period. Algert Global LLC’s holdings in TG Therapeutics were worth $1,477,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of TGTX. Vanguard Group Inc. grew its holdings in TG Therapeutics by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock worth $469,454,000 after acquiring an additional 209,190 shares during the period. Clearbridge Investments LLC acquired a new position in shares of TG Therapeutics in the 4th quarter worth approximately $55,237,000. Northern Trust Corp raised its holdings in shares of TG Therapeutics by 8.6% in the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock worth $46,141,000 after purchasing an additional 120,785 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in TG Therapeutics by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company’s stock valued at $38,212,000 after purchasing an additional 84,904 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in TG Therapeutics by 1.2% during the fourth quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company’s stock worth $27,985,000 after buying an additional 10,989 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

Analyst Ratings Changes

TGTX has been the topic of several research reports. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.80.

TG Therapeutics Price Performance

TGTX opened at $33.64 on Friday. The firm has a market capitalization of $5.34 billion, a P/E ratio of -336.37 and a beta of 2.21. The stock has a fifty day moving average of $38.90 and a 200-day moving average of $33.56. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 12-month low of $15.16 and a 12-month high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.16). The business had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company’s revenue was up 90.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.07) earnings per share. Equities analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.